Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salix Pharmaceuticals Ltd SLXP

Healthcare Drug Manufacturers - Specialty & Generic

Recent & Breaking News (NDAQ:SLXP)

Salix Pharmaceuticals and Cosmo Technologies Announce Termination of Merger Agreement

Business Wire October 3, 2014

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

Business Wire September 29, 2014

Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN® 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea

Business Wire September 18, 2014

Salix Secures Additional Intellectual Property Relating to Rifaximin

Business Wire September 18, 2014

UCERIS® (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA

Business Wire September 15, 2014

Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea

Business Wire September 2, 2014

Salix Announces Early Termination of HSR Waiting Period for Pending Transaction

Business Wire August 19, 2014

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Salix Pharmaceuticals, Ltd. of Class Action Against Its Board of Directors In Connection With the Sale of the Company to Cosmo Technologies Limited -- SLXP

Marketwired August 13, 2014

Salix Announces Important Topline Results for Microbiome, Culture & Susceptibility, and Key Secondary Efficacy Results for TARGET 3, Rifaximin IBS-D Repeat Treatment Study

Business Wire August 11, 2014

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Salix Pharmaceuticals, Ltd. of Class Action Against Its Board of Directors In Connection With the Sale of the Company to Cosmo Technologies Limited -- SLXP

GlobeNewswire August 11, 2014

FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain

Business Wire August 11, 2014

Salix Pharmaceuticals Reports 2Q2014 Results

Business Wire August 7, 2014

INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. to Cosmo Pharmaceuticals S.p.A

Business Wire August 1, 2014

Lifshitz & Miller Law Firm Announces Investigation of Design Within Reach, Inc., Family Dollar Stores, Inc., GFI Group Inc., Intermountain Community Bancorp, Rockwood Holdings, Inc., and Salix Pharmaceuticals Ltd.

PR Newswire July 31, 2014

INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. - SLXP

PR Newswire July 28, 2014

Salix Pharmaceuticals Announces 2Q2014 Financial Results Conference Call and Webcast

Business Wire July 24, 2014

INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd.

Business Wire July 21, 2014

Salix and Pharming Announce FDA Approval of RUCONEST® for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)

Business Wire July 17, 2014

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Salix Pharmaceuticals, Ltd. and Its Board of Directors In Connection With the Sale of the Company to Cosmo Technologies Limited

Business Wire July 15, 2014

Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for Patients With Chronic Non-Cancer Pain

GlobeNewswire July 14, 2014